title: Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
abstract: OBJECTIVE
  To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen.
  
  
  METHODS
  Forty consecutive patients with stage III or IV epithelial ovarian cancer or advanced or recurrent endometrial cancer were treated with ultra-high-dose cisplatin-carboplatin chemotherapy. No patient had received prior chemotherapy. Chemotherapy consisted of intravenous (IV) cisplatin 70 mg/m2 and IV carboplatin 100 mg/m2 administered on days 1 and 8 every 28 days for five cycles, representing a total monthly organoplatin dose of 207 mg/m2. Patients were randomized to receive metoclopramide, diphenhydramine, prochlorperazine, and lorazepam; or ondansetron, dexamethasone, prochlorperazine, and lorazepam. Patients were blinded and there was no crossover. The metoclopramide dose was 2 mg/kg IV every 2 hours x 3, and the ondansetron dose was 0.15 mg/kg IV every 4 hours x 3.
  
  
  RESULTS
  All 40 patients developed vomiting; 21 (52%) developed severe vomiting and seven (17%) required home IV therapy (grade 4). Eight patients (40%) receiving the metoclopramide regimen developed severe vomiting, compared to 13 (65%) in the ondansetron group (P = .50). Two patients (10%) in the metoclopramide group developed grade 4 vomiting, compared to five (25%) in the ondansetron group (P = .45). Except for sedation and amnesia, there were no significant side effects associated with either regimen.
  
  
  CONCLUSIONS
  Neither regimen was effective in preventing high-dose cisplatin-carboplatin-induced emesis, and the ondansetron regimen did not appear to be superior.
authors.affiliation: Division of Gynecologic Oncology, Southern Illinois University School of Medicine, Springfield.
authors.forename: J
authors.initials: J
authors.lastname: Fanning
authors.forename: R D
authors.initials: RD
authors.lastname: Hilgers
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003907:Dexamethasone / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008787:Metoclopramide / Q000627:therapeutic use*; D017294:Ondansetron / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011346:Prochlorperazine / Q000627:therapeutic use; D012720:Severity of Illness Index; D016037:Single-Blind Method; D017211:Treatment Failure; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D017294:Ondansetron; D003907:Dexamethasone; D004155:Diphenhydramine; D016190:Carboplatin; D008787:Metoclopramide; D008140:Lorazepam; D002945:Cisplatin; D011346:Prochlorperazine